A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

Summary

This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.

Timeline

Start

2026-04

Primary completion

2028-10

Completion

2029-10

Drugs

Indications